KWMG
ALT icon

King Wealth Management Group’s Altimmune ALT Stock Holding History

King Wealth Management Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,000
Closed -$117K – 153
2022
Q2 		$117K Buy
+10,000
New +$61.7K 0.03% 154

Other funds holding ALT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

King Wealth Management Group's ALT Position: Q3 2022 in Review

King Wealth Management Group sold out of Altimmune (ALT) in Q3 2022, closing a stake of 10,000 shares — an estimated $117K sold.

King Wealth Management Group first reported a position in ALT in Q2 2022 and held it in 1 quarter. The position peaked at $117K in Q2 2022. 122 funds tracked by Wall St. Rank hold ALT as of Q3 2022.

  • King Wealth Management Group reported no remaining Altimmune position as of Q3 2022 after selling out during the quarter.
  • King Wealth Management Group sold 10,000 Altimmune shares in Q3 2022, an estimated $117K.
  • King Wealth Management Group first reported a position in Altimmune in Q2 2022 and held it in 1 quarter.
  • King Wealth Management Group's Altimmune position peaked at $117K in Q2 2022.
  • 122 funds tracked by Wall St. Rank held Altimmune as of Q3 2022.

Based on King Wealth Management Group's 13F filing for Q3 2022, filed 10 Nov 2022.